One2Treat, The Company
One2Treat is a fast-growing tech company incorporating the patient voice in all strategic decisions about treatment assessments in Pharma R&D. One2Treat is dedicated to transforming the way biopharmaceutical companies design and evaluate clinical trials, and how the overall medical value of a treatment may be communicated, by integrating multiple meaningful dimensions in the treatment assessment
OUR VISION
Through its innovative solutions, One2Treat envisions a future where clinical decisions are driven by what truly matters to patients, enabling a more personalized, preference-aligned care.
OUR MISSION
One2Treat’s mission is to develop methods and advanced software that enable a holistic evaluation of treatment effects by integrating all key patient-relevant outcomes into a single comprehensive assessment of the Net Treatment Benefit.
OUR UNIQUE VALUE
PROPOSITION
One2Treat applies state-of-the-art computing to the large volumes of patient data collected in clinical trials and supportive real-world evidence. This allows us to undertake more clinically meaningful statistical analysis of treatment effects, incorporating all outcomes that matter to patients. As a result, our approach significantly reduces trial sample sizes and expedites innovative treatments time to market.
ADVISORY BOARD
MEMBERS
- Rob Nichols
- Marc Buyse
- Damien Tremolet